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Abstract
Background: The neutrophil-to-lymphocyte ratio (NLR), a simple marker of the systemic inflammatory response, has
been demonstrated to correlate with patient outcomes for various solid malignancies. We investigated the utility of
the pretreatment NLR as a prognosticator in patients who presented with penile cancer.
Methods: A total of 41 patients who underwent complete blood count with differential and subsequent radical
penectomy from 1988 to 2014 were analyzed. We assessed the correlation between the NLR and the prognosis of
penile cancer.
Results: The median and mean (± SD) NLRs in 41 penile cancer patients were 3.42 and 5.03 ± 4.99, respectively.
Based on the area under receiver operator characteristic curve, the cut-off value of NLR was determined to be 2.82.
Patients with a high NLR (≥2.82) showed a significantly poorer cancer-specific survival (p = 0.023) than those with a
low NLR.
Conclusions: The pretreatment NLR may function as a biomarker that precisely predicts the prognosis in patients
with penile cancer.
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Background
Penile squamous cell carcinoma (PSCC) is a rare disease
in developed countries, with an incidence of 0.3–1.0 per
100,000 males in Europe and North America and 0.4–
0.5 per 100,000 males in Japan [1, 2]. However, it repre-
sents an important public health problem for developing
countries in Asia, Africa and South America, where its
incidence varies from 3 to 8.3 cases per 100,000 [3]. The
major prognostic factors in PSCC are tumor grade and
the presence of perineal and lymphatic invasion [4]. SCC,
a soluble epithelial antigen and a classical molecular
marker lacks sensitivity in the detection of small tumor
burdens and has little prognostic significance in survival
after surgery [5]. The overexpression of p53 and Ki-67
and the loss of membranous E-cadherin determined
immunohistochemically in biopsy or penectomy tissue
specimens are also shown to associate with the detection
of lymph node metastases, but these markers are not
useful in clinical practice [4, 6].
The neutrophil-to-lymphocyte ratio (NLR) has been
suggested as a simple marker of the systemic inflamma-
tory response in critical care patients [7]. It has also
been reported as an independent prognostic factor for
several solid malignancies [8–17]. Importantly, the NLR
can easily be calculated from routine complete blood
counts (CBCs) in peripheral blood samples [15, 16].
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We investigated the utility of the pretreatment NLR as




A total of 73,637 CBC exams, which included absolute neu-
trophil and lymphocyte counts, were performed in 9782
male patients at the Department of Urology, Yokohama
City University Hospital (Yokohama, Japan) from 1999 to
2015. Among these, we investigated the NLRs in patients
with urological diseases, such as penile cancer, renal cell
carcinoma, prostate cancer, testicular cancer, overactive
bladder, and benign prostatic hyperplasia (Fig. 1).
We conducted a retrospective study of 41 patients with
penile cancer who underwent CBCs and subsequent
radical penectomy at Yokohama City University Medical
Center and 24 other institutions from 1988 to 2014. Some
of the patients who were diagnosed at Yokohama City
University Hospital overlapped with those in a study of
9782 male patients. All of the patients were pathologically
diagnosed with PSCC. Patients were followed-up for 2.3–
271.7 months (median: 34.7 months). The incidence of
tumor relapse and patient outcomes during the follow-up
period were evaluated. This study was approved by the
ethics committee of Yokohama City University, Yokohama
City University Medical Center and the other participating
institutions approved the protocol of the present study.
Written informed consent was obtained from the penile
cancer patients.
Clinical and laboratory assessments
The NLR was calculated using the neutrophil and
lymphocyte counts, which were obtained via CBCs be-
fore the surgery. We determined the cut-off point of the
NLR according to the sensitivity and specificity levels
derived from area under receiver operator characteristic
(AUROC) curve.
Immunohistochemistry
An immunohistochemical analysis was performed in 5-
μm-thick tissue microarray (TMA) sections, including
183 penile tissue specimens that were obtained from US
Biomax (PE2081, Rockville, MD). Immunohistochemical
staining was performed., as described previously [18],
using a primary antibody to CD66b (clone G10F5, diluted
to 1:200, BD Biosciences, San Jose, CA, USA) or CD8
(clone C8/144B, diluted to 1:100, DAKO Corporation,
Carpenteria, CA, USA), to detect tumor-infiltrating
neutrophils and lymphocytes, respectively. The slides were
then examined by a single pathologist (HM) who was
blinded to the identity of the samples. The total numbers of
CD66b-positive and CD8-positive cells were counted in
each TMA core. Due to the small number benign speci-
mens and some of the specimens including infection, we
did not compare between benign and malignant specimens.
Statistical analyses
The patients’ characteristics and preoperative factors were
analyzed using the Mann–Whitney U and chi-squared
tests, using the Graph Pad Prism software program
(Graph Pad Software, La Jolla, CA, USA). The survival
duration was defined as the time between the dates of
pathological diagnosis and tumor progression or death. A
log-rank test was performed for comparison between
higher and lower NLR groups. Multivariate logistic regres-
sion models were used to detect the individual factors.
P values of <0.05 were considered to indicate statis-
tical significance.
Results
Penile cancer patients showed a higher NLR
According to the clinical database of the Department of
Urology at Yokohama City University Hospital, 9782 pa-
tients underwent an NLR check during the study period.
The median/mean NLRs for each disease (mainly the
names of the diagnosed diseases which were used for
Fig. 1 The NLRs in patients with urological diseases. Each value represents the mean and 95 % confidence interval
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medical insurance) were 3.42/5.03 (penile cancer), 2.67/
4.67 (bladder cancer), 2.64/4.40 (renal cell carcinoma),
(2.39/4.37 (renal pelvic cancer), 3.58/4.35 (adrenal can-
cer), 2.51/4.20 (ureteral cancer), 2.39/3.65 (testicular
cancer), 2.26/3.28 (prostatic cancer), 2.22/3.23 (benign
prostatic hyperplasia), and 2.41/2.68 (overactive bladder)
(Fig. 1). The NLR of the PSCC patients was significantly
higher than the NLRs of testicular cancer (p <0.05),
prostate cancer (p <0.01), benign prostate hyperplasia
(p < 0.01), and overactive bladder (p <0.001) patients.
The NLR predicts the survival of penile cancer patients
The median and mean (± SD) ages of the 41 patients
were 69 and 68.5 (±11.4) years with median and mean
(± SD) follow-up periods of 34.7 and 60.7 (±52.1)
months after the initial diagnosis. The clinicopathological
data of these patients are summarized in Table 1.
We created an AUROC curve to determine the NLR
cut-off value for predicting the prognosis of penile can-
cer patients. The cut-off value was determined to be
2.82. High NLR was significantly associated with lymph
node metastasis (p = 0.049). Patients with high NLRs also
showed a significantly poorer cancer-specific survival
(p = 0.023) than those with low NLRs (Fig. 2a). In addition,
patients with high NLRs tended to correlate with poorer
overall survival (p = 0.076) (Fig. 2b). We performed a
multivariate analysis but it did not reveal any significant
independent factors that predicted the prognosis.
Tumor-infiltrating neutrophils and lymphocytes in PSCC
Immunohistochemistry was used to determine the num-
bers of tumor-infiltrating neutrophils and lymphocytes in
the penile TMA. Both CD66b- and CD8-positive immune
cells were present in the specimens (Fig. 3). We then ana-
lyzed the relationship between the number of tumor-
infiltrating CD66b-positive neutrophils or CD8-positive
lymphocytes and tumor grade or stage. There were
no statistically significant correlations between the number
of CD66b- or CD8-positive cells and tumor grade. Interest-
ingly, the number of CD66b-positive cells, but not that of
CD8-positive cells, was significantly lower in high stage
disease, compared with stage 1 disease (p = 0.014). How-
ever, there were no statistically significant differences in the
ratio of CD66b/CD8-positive cell Table 2.
Discussion
We have evaluated the pretreatment NLR as a predictor
of survival in penile cancer patients. We found that
high NLRs were associated with a poorer prognosis of
penile cancer.
Several prognostic factors have been established for
patients with penile cancer. Nodal metastasis is the most
important predictor of a poor clinical outcome [4]. Tumor
grade and perineural or lymphatic invasion are also
known prognostic predictors. p53, Ki-67, E-cadherin, and
epidermal growth factor receptor (EGFR) are considered
to be molecular prognostic markers, but they are not
always useful in clinical practice [4, 6].
It has been suggested that the NLR can be used to
estimate the magnitude of systemic inflammation in
cancer patients [8, 18–20]. The NLR is easily and in-
expensively measured [21]. An elevated NLR has been
reported to be associated with a poorer survival rate
in a variety of cancers [8–13, 22].
Pond et al. demonstrated that the NLR was significantly
associated with survival in 26 patients with penile cancer
[21]. This has been the only paper to describe the relation-
ship between the NLR and the prognosis of penile cancer;
however, the subjects were limited to patients who were
undergoing concurrent chemo-radiotherapy.
Table 1 Patients’ characteristics
Variables number or median (mean ± SD) p value
all NLR < 2.82 NLR≥ 2.82
A number of
patients.
41 (100.0 %) 21 (51.2 %) 20 (48.8 %)
Age (years) 69 (68.5 ± 11.8) 69 (66.3 ± 10.9) 71 (70.7 ± 12.5) 0.243
Location
Gland 30 (73.2 %) 15 (57.1 %) 15 (75.0 %) 0.287
Foreskin 8 (19.5 %) 5 (23.8 %) 3 (15.0 %)
Shaft 2 (4.9 %) 0 (0.0 %) 2 (10.0 %)
Unknown 1 (2.4 %) 1 (4.8 %) 0 (0.0 %)
Tumor grade (differentiation)
Well 26 (63.4 %) 15 (57.1 %) 11 (55.0 %) 0.330
Moderate 10 (24.0 %) 3 (14.3 %) 7 (35.0 %)
Poor 2 (4.9 %) 1 (4.8 %) 1 (5.0 %)
Unknown 3 (7.3 %) 2 (9.5 %) 1 (5.0 %)
Pathological T stage
1 22 (53.7 %) 14 (66.7 %) 8 (40.0 %) 0.273
2 13 (31.’%) 4 (19.0 %) 9 (45.0 %)
3 2 (4.9 %) 1 (4.8 %) 1 (5.0 %)
4 3 (7.3 %) 1 (4.8 %) 2 (10.0 %)
Unknown 1 (2.4 %) 1 (4.8 %) 0 (0.0 %)
Lymph node
metastasis
9 (21.6 %) 2 (9.5 %) 7 (35.0 %) 0.049
Distant
metastasis
1 (2.4 %) 1 (4.8 %) 0 (0.0 %) 0.323
Anatomic stage
I 17 (41.5 %) 10 (47.6 %) 7 (35.0 %) 0.214
II 14 (34.1 %) 8 (38.1 %) 6 (30.0 %)
III 3 (7.3 %) 0 (0.0 %) 3 (15.0 %)
IV 6 (14.6 %) 2 (9.5 %) 4 (20.0 %)
Unknown 1 (2.4 %) 1 (4.8 %) 0 (0.0 %)
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The AUROC determined the cut-off value of the NLR
to be 2.82 in the present study. Several studies in pa-
tients with advanced pancreatic cancer have shown NLR
cut-off values of approximately five [8]. In patients with
intrahepatic cholangiocarcinoma and those with liver
metastasis from colorectal carcinoma [9], the NLR cut-
off value is also set at five. In urological cancers, an NLR
cut-off value of approximately five has been used for
prostate cancer, while scores of 2 to 5 have been used
for renal cell carcinoma [23]. Our cut-off point for the
NLR was thus somewhat lower than the values determined
in previous studies, despite the fact that the NLR for penile
cancer was high in comparison to other urological diseases.
Of note, in most of these studies [ref], the NLR was
assessed in advanced cases. On the other hand, in our pre-
vous study [24], the NLR cut-off point for predicting the
prognosis of patients most of who had organ-confined
prostate cancer was 2.4.
In recent studies, the preoperative levels of C-reactive
protein (CRP) were found to predict survival in patients
with penile squamous cell carcinoma [24, 25]. In various
tumors, other markers of the systemic inflammatory
response have also been developed to predict patient
outcomes, such as the platelet-to-lympocyte ratio (PLR),
the lympocyte-to-monocyte ratio (LMR), and the
preoperative haemogolobin and albumin levels [26–31].
It is necessary to investigate the relationship between
these markers and the prognosis of penile cancer in the
future.
The management of the regional lymph nodes in
penile cancer patients is highly important for long-term
survival. However, there is no non-invasive or minimally
invasive staging technique that can be used to determine
their lymph node status. Proven molecular markers or
accurate minimally invasive tests which can be used to
identify nodal metastasis are desired.
The present study is associated with some limitations
due to its retrospective nature. Our patients received a
variety of therapies, including surgery, chemotherapy, ra-
diation therapy, other treatments, and their combina-
tions. Although the treatment options were
heterogeneous, we found that the NLR was associated
with patient outcomes. Second is that we did not per-
form mechanistic experiments to determine the roles of
neutrophils and/or lymphocytes in penile cancer progres-
sion. Nonetheless, the current results support the findings
of previous studies indicating correlations between the
NLR/inflammation and the clinical outcome of patients
with several types of advanced-stage solid tumors. Third,
the sample size was low because of the low incidence of
Fig. 2 The correlation between the NLR and a cancer-specific survival or b overall survival
Fig. 3 Immunohistochemistry of a CD66b and b CD8 in penile cancer specimens. CD66b- and CD8-positive immune cells are seen predominantly
in the stromal tissue
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penile cancer and the lack of some information, including
the degree of extranodal extension [32]. Despite this limi-
tation, the population of the present study represents the
largest number of penile cancer patients in whom the
NLR was investigated. An additional limitation is that the
data in the clinical database study was extracted electron-
ically. Thus, the detailed information about the specific
diseases was not confirmed, while the technique
allowed us to obtain a large number of cases.
Our immunohistochemistry revealed no significant
correlations between the number of tumor-infiltrating
CD66b- or CD8-positive immune cells and tumor grade
or stage. Nonetheless, higher number of CD66b-positive
neutrophils was correlated with lower tumor stage. Wang
et al. showed that increased tumor-infiltrating neutrophils
and neutrophil-to-lymphocyte ratio in esophageal cancer
specimens correlated with disease progression [33].
Although a large number of studies have demonstrated
the prognostic value of NLR in various solid tumors,
others have failed to show that of tumor-infiltrating
neutrophils/lymphocytes in tissue specimens. We indeed
performed immunohistochemical staining for CD66b and
CD8 in bladder cancer and prostate cancer specimens, but
found no significant correlations between the number of
immunoreactive immune cells and patient outcomes
(unpublished data).
Conclusion
NLR was found to correlate with lymph node metastasis as
well as cancer-specific survival in patients with PSCC. Our
data thus suggest that the NLR serves as a biomarker
which predicts the patient outcomes.
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